文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2022 年 4 月至 6 月，葡萄牙奥密克戎 BA.5 波期间特定 SARS-CoV-2 抗体的血清流行率。

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.

出版信息

Emerg Infect Dis. 2023 Feb;29(3):590-594. doi: 10.3201/eid2903.221546. Epub 2023 Feb 2.

DOI:10.3201/eid2903.221546
PMID:36732078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9973687/
Abstract

After the rapid spread of SARS-CoV-2 BA.5 Omicron lineage in Portugal, we developed a seroepidemiologic survey based on a sample of 3,825 residents. Results indicated that from April 27 through June 8, 2022, the estimated seroprevalence of SARS-CoV-2 nucleocapsid or spike IgG was 95.8%, which indicates a high level of protection.

摘要

在 SARS-CoV-2 BA.5 奥密克戎谱系在葡萄牙迅速传播后，我们基于 3825 名居民的样本开展了血清流行病学调查。结果表明，2022 年 4 月 27 日至 6 月 8 日，SARS-CoV-2 核衣壳或刺突 IgG 的估计血清阳性率为 95.8%，表明保护水平较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc9/9973687/09c2fa9b7f6a/22-1546-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc9/9973687/b94858a7067c/22-1546-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc9/9973687/09c2fa9b7f6a/22-1546-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc9/9973687/b94858a7067c/22-1546-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddc9/9973687/09c2fa9b7f6a/22-1546-F2.jpg

相似文献

[1]
Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.

Emerg Infect Dis. 2023-2

[2]
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).

Acta Med Port. 2021-2-1

[3]
SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).

Infect Dis (Lond). 2022-6

[4]
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.

Emerg Infect Dis. 2023-3

[5]
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.

Emerg Infect Dis. 2022-6

[6]
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.

PLoS One. 2023

[7]
Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal.

Emerg Infect Dis. 2021-11

[8]
SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.

Acta Med Port. 2023-1-2

[9]
SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.

Emerg Infect Dis. 2022-11

[10]
Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022.

J Korean Med Sci. 2024-2-5

引用本文的文献

[1]
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.

Commun Med (Lond). 2025-5-3

[2]
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.

BMC Infect Dis. 2024-8-20

[3]
SARS-CoV-2 seroprevalence among Beninese pregnant women in the third year of the pandemic.

BMC Public Health. 2024-7-2

[4]
Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.

Heliyon. 2024-4-12

[5]
Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea.

Front Immunol. 2023

本文引用的文献

[1]
Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.

CMAJ. 2022-12-5

[2]
SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021.

Acta Med Port. 2023-1-2

[3]
SARS-CoV-2 Seroprevalence Among School-Age Children in Milan: How Has It Changed With the Fourth Pandemic Wave?

Pediatr Infect Dis J. 2022-8-1

[4]
Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination.

Vaccines (Basel). 2022-1-20

[5]
Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications.

Emerg Infect Dis. 2022-3

[6]
SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).

Infect Dis (Lond). 2022-6

[7]
Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.

Infection. 2022-4

[8]
Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).

Acta Med Port. 2021-2-1

[9]
Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.

Public Health. 2021-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索